XML 87 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)
 12 Months Ended
Dec. 31, 2021
Novartis Institutes for BioMedical Research, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202120202019
Revenue related to Novartis agreement:
Recognition of upfront license fee$29,945 $4,143 $— 
Research services7,999 1,109 — 
Total$37,944 $5,252 $— 
Biogen MA, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202120202019
Revenue related to Biogen agreement:
Recognition of license and stand-ready fee$29,224 $21,356 $— 
Research services13,076 6,545 — 
Total$42,300 $27,901 $— 
Kite Pharma, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202120202019
Revenue related to Kite agreement:
Recognition of license and stand-ready fee$24,977 $25,046 $24,977 
Research services476 3,562 9,373 
Total$25,453 $28,608 $34,350 
Pfizer, Giroctocogene Fitelparvovec  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202120202019
Revenue related to Pfizer giroctocogene fitelparvovec agreement:
Recognition of upfront fee and research services$— $3,111 $15,697 
Milestone achievement— 31,338 23,662 
Total$— $34,449 $39,359 
Pfizer C9ORF72  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202120202019
Revenue related to Pfizer C9ORF72 agreement:
Recognition of upfront fee$— $7,985 $1,827 
Milestone achievement— 5,000 — 
Total$— $12,985 $1,827 
Sanofi S.A.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202120202019
Revenue related to Sanofi agreement:
Recognition of upfront fee$34 $298 $3,494 
Research services3,057 4,823 6,367 
Milestone achievement23 201 12,819 
Total$3,114 $5,322 $22,680